Author

B. Faezov

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

R. L. Dunbrack· 2 shared B. J. Groendyke· 1 shared E. S. Fischer· 1 shared E. V. Demidova· 1 shared G. Abalakov· 1 shared H.-Y. Chow· 1 shared J. Adolf-Bryfogle· 1 shared J. Chernoff· 1 shared

Activity by Year

2022-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

R. L. Dunbrack

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Co-occurring mutations in the POLE exonuclease and non-exonuclease domains define a unique subset of highly mutagenic tumors.

S. S. Shah, E. V. Demidova, S. Ringenbach, B. Faezov, M. Andrake, P. Mur, J. Viana-Errasti, J. Xiu, J. Swensen, L. Valle, R. Dunbrack, M. J. Hall, S. Arora

The paper identifies co-occurring POLE mutations in both exonuclease and non-exonuclease domains as a novel driver of ultra-high tumor mutation burden in certain cancers.

bioRxiv · Dec 15, 2022 · PreprintCancer Biology

A penultimate classification of canonical antibody CDR conformations

S. Kelow, B. Faezov, Q. Xu, M. I. Parker, J. Adolf-Bryfogle, R. L. Dunbrack

The paper updates the classification of antibody CDR conformations using improved clustering methods and electron density validation, identifying new clusters and retiring outdated ones.

bioRxiv · Oct 12, 2022 · PreprintImmunology

Development and utility of a PAK1-selective degrader

H.-Y. Chow, S. Karchugina, B. J. Groendyke, S. Toenjes, J. Hatcher, K. A. Donovan, E. S. Fischer, G. Abalakov, B. Faezov, R. L. Dunbrack, N. S. Gray, J. Chernoff

This study develops a PAK1-selective degrader, BJG-05-039, which shows enhanced anti-proliferative effects compared to the parent inhibitor NVS-PAK1-1 in PAK1-dependent cell lines.

bioRxiv · May 12, 2022Cancer Biology